The Escitalopram versus Electric Current Therapy for Treating Depression Clinical Study (ELECT-TDCS): Rationale and study design of a non-inferiority, triple-arm, placebo-controlled clinical trial;Estudo clinico Escitalopram versus Eletroterapia no Tratamento da Depressao (ELECT-TDCS): Racional e desenho de estudo de um ensaio de nao inferioridade, de tres bracos, placebo-controlado

Sao Paulo Medical Journal

Volumn 133, Issue 3, 2015, Pages 252-263

  Brunoni, André Russowsky ^a   Sampaio, Bernardo ^a   Moffa, Adriano Henrique ^a   Borrione, Lucas ^a   Nogueira, Barbara Schwair ^a   Aparício, Luana Vanessa Marotti ^a   Veronezi, Beatriz ^a   Moreno, Marina ^a   Fernandes, Raquel Albano ^a   Tavares, Diego ^a   Bueno, Priscila Vilela Silveira ^a   Seibt, Ole ^b   Bikson, Marom ^b   Fraguas, Renerio ^a   Benseñor, Isab Ela Martins ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b CITY UNIVERSITY OF NEW YORK   (United States)

Author keywords

Biological markers; Citalopram; Depressive disorder; Electric stimulation therapy; Major; Randomized controlled trial

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; ESCITALOPRAM; NEUROTROPHIN; PLACEBO; ANTIDEPRESSANT AGENT; CITALOPRAM;

ADULT; AGED; ANODE; ARTICLE; BURN; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG DOSE TITRATION; DRUG EFFICACY; ELECTRIC CURRENT THERAPY; ELECTRODE; FEMALE; GENERAL DEVICE; GENETIC POLYMORPHISM; HAMILTON DEPRESSION RATING SCALE; HEART RATE VARIABILITY; HUMAN; MALE; MEDICAL PROCEDURES; MINI INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MONTREAL COGNITIVE ASSESSMENT; MOTOR CORTEX; NERVE CELL EXCITABILITY; NEUROIMAGING; PHASE 3 CLINICAL TRIAL; POSITIVE AND NEGATIVE AFFECT SCHEDULE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; YOUNG MANIA RATING SCALE; ADOLESCENT; ANALYSIS OF VARIANCE; CLINICAL TRIAL; DEPRESSIVE DISORDER, MAJOR; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PLACEBO EFFECT; PROCEDURES; PSYCHOLOGICAL RATING SCALE; REPRODUCIBILITY; TIME; TRANSCRANIAL DIRECT CURRENT STIMULATION; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CITALOPRAM; COMBINED MODALITY THERAPY; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MALE; MIDDLE AGED; PLACEBO EFFECT; PSYCHIATRIC STATUS RATING SCALES; REPRODUCIBILITY OF RESULTS; TIME FACTORS; TRANSCRANIAL DIRECT CURRENT STIMULATION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84937426363     PISSN: 15163180     EISSN: None     Source Type: Journal    
DOI: 10.1590/1516-3180.2014.00351712     Document Type: Article

References (96)

1. Bromet E, Andrade LH, Hwang I, et al. Cross-national epidemiology of DSM-IV major depressive episode. BMC Med. 2011;9:90.
2. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet. 1997;349(9064):1498-504.
3. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longerterm outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006; 163(11):1905-17.
4. Anderson IM, Ferrier IN, Baldwin RC, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol. 2008;22(4):343-96.
5. Rosa MA, Lisanby SH. Somatic treatments for mood disorders. Neuropsychopharmacology. 2012;37(1):102-16.
6. George MS, Lisanby SH, Avery D, et al. Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a shamcontrolled randomized trial. Arch Gen Psychiatry. 2010;67(5):507-16.
7. Schutter DJ. Antidepressant efficacy of high-frequency transcranial magnetic stimulation over the left dorsolateral prefrontal cortex in double-blind sham-controlled designs: a meta-analysis. Psychol Med. 2009;39(1):65-75.
8. Priori A, Hallett M, Rothwell JC. Repetitive transcranial magnetic stimulation or transcranial direct current stimulation? Brain Stimul. 2009;2(4):241-5.
9. Brunoni AR, Nitsche MA, Bolognini N, et al. Clinical research with transcranial direct current stimulation (tDCS): challenges and future directions. Brain Stimul. 2012;5(3):175-95.
10. Brunoni AR, Amadera J, Berbel B, et al. A systematic review on reporting and assessment of adverse effects associated with transcranial direct current stimulation. Int J Neuropsychopharmacol. 2011;14(8):1133-45.
11. Nitsche MA, Paulus W. Excitability changes induced in the human motor cortex by weak transcranial direct current stimulation. J Physiol. 2000;527 Pt 3:633-9.
12. Purpura DP, McMurtry JG. Intracellular activities and evoked potential changes during polarization of motor cortex. J Neurophysiol. 1965;28:166-85.
13. Radman T, Ramos RL, Brumberg JC, Bikson M. Role of cortical cell type and morphology in subthreshold and suprathreshold uniform electric field stimulation in vitro. Brain Stimul. 2009;2(4): 215-28, 228. e1-3.
14. Batsikadze G, Moliadze V, Paulus W, Kuo MF, Nitsche MA. Partially non-linear stimulation intensity-dependent effects of direct current stimulation on motor cortex excitability in humans. J Physiol. 2013;591(Pt 7):1987-2000.
15. Rahman A, Reato D, Arlotti M, et al. Cellular effects of acute direct current stimulation: somatic and synaptic terminal effects. J Physiol. 2013;591(Pt 10):2563-78.
16. Mayberg HS, Brannan SK, Tekell JL, et al. Regional metabolic effects of fluoxetine in major depression: serial changes and relationship to clinical response. Biol Psychiatry. 2000;48(8):830-43.
17. Moffa AH, Valiengo L, Shiozawa P, Brunoni AR. Novas neuroterapeuticas em psiquiatria: racional e uso da estimulacao transcraniana por corrente continua no transtorno depressive maior [Novel neurotherapeutics in psychiatry: use and rationale of transcranial direct current stimulation in major depressive disorder]. Rev Psiquiatr Clin. (Sao Paulo). 2014;41(1):15-20.
18. Ferrucci R, Bortolomasi M, Brunoni A, et al. Comparative benefits of transcranial direct current stimulation (tDCS) treatment in patients with mild/moderate vs. severe depression. Clinical Neuropsychiatry.2009;6(6):246-51. Available from: http://www.clinicalneuropsychiatry.org/pdf/03%20ferrucci.pdf. Accessed in 2015 (Jan 7).
19. Schutter DJ. Quantitative review of the efficacy of slow-frequency magnetic brain stimulation in major depressive disorder. Psychol Med. 2010;40(11):1789-95.
20. Brunoni AR, Ferrucci R, Fregni F, Boggio PS, Priori A. Transcranial direct current stimulation for the treatment of major depressive disorder: a summary of preclinical, clinical and translational findings. Prog Neuropsychopharmacol Biol Psychiatry. 2012;39(1):9-16.
21. Fregni F, Boggio PS, Nitsche MA, et al. Treatment of major depression with transcranial direct current stimulation. Bipolar Disord. 2006;8(2):203-4.
22. Loo CK, Alonzo A, Martin D, et al. Transcranial direct current stimulation for depression: 3-week, randomised, sham-controlled trial. Br J Psychiatry. 2012;200(1):52-9.
23. Brunoni AR, Valiengo L, Baccaro A, et al. The sertraline vs. electrical current therapy for treating depression clinical study: results from a factorial, randomized, controlled trial. JAMA Psychiatry. 2013;70(4):383-91.
24. Shiozawa P, Fregni F, Benseens IM, et al. Transcranial direct current stimulation for major depression: an updated systematic review and meta-analysis. Int J Neuropsychopharmacol. 2014;17(9):1443-52.
25. Loo CK, Sachdev P, Martin D, et al. A double-blind, sham-controlled trial of transcranial direct current stimulation for the treatment of depression. Int J Neuropsychopharmacol. 2010;13(1):61-9.
26. Palm U, Schiller C, Fintescu Z, et al. Transcranial direct current stimulation in treatment resistant depression: a randomized doubleblind, placebo-controlled study. Brain Stimul. 2012;5(3):242-51.
27. Blumberger DM, Tran LC, Fitzgerald PB, Hoy KE, Daskalakis ZJ. A randomized double-blind sham-controlled study of transcranial direct current stimulation for treatment-resistant major depression. Front Psychiatry. 2012;3:74.
28. Brunoni AR, Valiengo L, Baccaro A, et al. Sertraline vs. Electrical Current Therapy for Treating Depression Clinical Trial--SELECT TDCS: design, rationale and objectives. Contemp Clin Trials. 2011;32(1):90-8.
29. Koch A, Roch AJ. Hypothesis testing in the “gold standard” design for proving the efficacy of an experimental treatment relative to placebo and a reference. J Biopharm Stat. 2004;14(2):315-25.
30. Gamalo MA, Muthukumarana S, Ghosh P, Tiwari RC. A generalized p-value approach for assessing noninferiority in a three-arm trial. Stat Methods Med Res. 2013;22(3):261-77.
31. Pigeot I, Schafer J, Rohmel J, Hauschke D. Assessing non-inferiority of a new treatment in a three-arm clinical trial including a placebo. Stat Med. 2003;22(6):883-99.
32. Binkley N, Bolognese M, Sidorowicz-Bialynicka A, et al. A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) trial. J Bone Miner Res. 2012;27(8):1821-9.
33. Gandiga PC, Hummel FC, Cohen LG. Transcranial DC stimulation (tDCS): a tool for double-blind sham-controlled clinical studies in brain stimulation. Clin Neurophysiol. 2006;117(4):845-50.
34. Nitsche MA, Cohen LG, Wassermann EM, et al. Transcranial direct current stimulation: State of the art 2008. Brain Stimul. 2008;1(3):206-23.
35. Brunoni AR, Schestatsky P, Lotufo PA, Bensenor IM, Fregni F. Comparison of blinding effectiveness between sham tDCS and placebo sertraline in a 6-week major depression randomized clinical trial. Clin Neurophysiol. 2014;125(2):298-305.
36. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multipletreatments meta-analysis. Lancet. 2009;373(9665):746-58.
37. Rabkin JG, Markowitz JS, Ocepek-Welikson K, Wager SS. General versus systematic inquiry about emergent clinical events with SAFTEE: implications for clinical research. J Clin Psychopharmacol. 1992;12(1):3-10.
38. Baccaro A, Brunoni AR, Bensenor IM, Fregni F. Hypomanic episode in unipolar depression during transcranial direct current stimulation. Acta Neuropsychiatrica. 2010;22(6):316-8. Available from: http://onlinelibrary.wiley.com/doi/10.1111/j.1601-5215.2010.00495.x/abstract. Accessed in 2015 (Jan 7).
39. Brunoni AR, Valiengo L, Zanao T, et al. Manic psychosis after sertraline and transcranial direct-current stimulation. J Neuropsychiatry Clin Neurosci. 2011;23(3):E4-5.
40. Arul-Anandam AP, Loo C, Mitchell P. Induction of hypomanic episode with transcranial direct current stimulation. J ECT. 2010;26(1):68-9.
41. Galvez V, Alonzo A, Martin S, et al. Hypomania induction in a patient with bipolar II disorder by transcranial direct current stimulation (tDCS). J ECT. 2011;27(3):256-8.
42. Kemp AH, Quintana DS, Gray MA. Impact of depression and antidepressant treatment on heart rate variability: a review and meta-analysis. Biol Psychiatry. 2010;67(11):1067-74.
43. Kemp AH, Brunoni AR, Santos IS, et al. Effects of depression, anxiety, comorbidity, and antidepressants on resting-state heart rate and its variability: an ELSA-Brasil cohort baseline study. Am J Psychiatry. 2014;171(2):1328-34.
44. Brunoni AR, Kemp AH, Dantas EM, et al. Heart rate variability is a trait marker of major depressive disorder: evidence from the sertraline vs. electric current therapy to treat depression clinical study. Int J Neuropsychopharmacol. 2013;16(9):1937-49.
45. Crisafulli C, Fabbri C, Porcelli S, et al. Pharmacogenetics of antidepressants. Front Pharmacol. 2011;16;2:6.
46. Kato M, Serretti A. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry. 2010;15(5):473-500.
47. Zanardi R, Magri L, Rossini D, et al. Role of serotonergic gene polymorphisms on response to transcranial magnetic stimulation in depression. Eur Neuropsychopharmacol. 2007;17(10):651-7.
48. Bocchio-Chiavetto L, Bagnardi V, Zanardini R, et al. Serum and plasma BDNF levels in major depression: a replication study and metaanalyses. World J Biol Psychiatry. 2010;11(6):763-73.
49. Malaguti A, Rossini D, Lucca A, et al. Role of COMT, 5-HT(1A), and SERT genetic polymorphisms on antidepressant response to Transcranial Magnetic Stimulation. Depress Anxiety. 2011;28(7):568-73.
50. Brunoni AR, Kemp AH, Shiozawa P, et al. Impact of 5-HTTLPR and BDNF polymorphisms on response to sertraline versus transcranial direct current stimulation: implications for the serotonergic system. Eur Neuropsychopharmacol. 2013;23(11):1530-40.
51. Du L, Bakish D, Lapierre YD, Ravindran AV, Hrdina PD. Association of polymorphism of serotonin 2A receptor gene with suicidal ideation in major depressive disorder. Am J Med Genet. 2000;96(1):56-60.
52. Van Oekelen D, Luyten WH, Leysen JE. 5-HT2A and 5-HT2C receptors and their atypical regulation properties. Life Sci. 2003;72(22):2429-49.
53. McMahon FJ, Buervenich S, Charney D, et al. Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet. 2006;78(5):804-14.
54. Jonsson EG, Goldman D, Spurlock G, et al. Tryptophan hydroxylase and catechol-O-methyltransferase gene polymorphisms: relationships to monoamine metabolite concentrations in CSF of healthy volunteers. Eur Arch Psychiatry Clin Neurosci. 1997;247(6):297-302.
55. Ventimiglia R, Mather PE, Jones BE, Lindsay RM. The neurotrophins BDNF, NT-3 and NT-4/5 promote survival and morphological and biochemical differentiation of striatal neurons in vitro. Eur J Neurosci. 1995;7(2):213-22.
56. Kuipers SD, Trentani A, Den Boer JA, Ter Horst GJ. Molecular correlates of impaired prefrontal plasticity in response to chronic stress. J Neurochem. 2003;85(5):1312-23.
57. Domschke K, Lawford B, Laje G, et al. Brain-derived neurotrophic factor (BDNF) gene: no major impact on antidepressant treatment response. Int J Neuropsychopharmacol. 2010;13(1):93-101.
58. Bocchio-Chiavetto L, Miniussi C, Zanardini R, et al. 5-HTTLPR and BDNF Val66Met polymorphisms and response to rTMS treatment in drug resistant depression. Neurosci Lett. 2008;437(2):130-4.
59. Stagg CJ, Nitsche MA. Physiological basis of transcranial direct current stimulation. Neuroscientist. 2011;17(1):37-53.
60. Kobayashi M, Pascual-Leone A. Transcranial magnetic stimulation in neurology. Lancet Neurol. 2003;2(3):145-56.
61. Hasler G, Northoff G. Discovering imaging endophenotypes for major depression. Mol Psychiatry. 2011;16(6):604-19.
62. Bajbouj M, Lisanby SH, Lang UE, et al. Evidence for impaired cortical inhibition in patients with unipolar major depression. Biol Psychiatry. 2006;59(5):395-400.
63. Levinson AJ, Fitzgerald PB, Favalli G, et al. Evidence of cortical inhibitory deficits in major depressive disorder. Biol Psychiatry. 2010;67(5):458-64.
64. Croarkin PE, Nakonezny PA, Husain MM, et al. Evidence for increased glutamatergic cortical facilitation in children and adolescents with major depressive disorder. JAMA Psychiatry. 2013;70(3):291-9.
65. Lai CH. Gray matter volume in major depressive disorder: a metaanalysis of voxel-based morphometry studies. Psychiatry Res. 2013;211(1):37-46.
66. Du MY, Wu QZ, Yue Q, et al. Voxelwise meta-analysis of gray matter reduction in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2012;36(1):11-6.
67. Bora E, Fornito A, Pantelis C, Yucel M. Gray matter abnormalities in Major Depressive Disorder: a meta-analysis of voxel based morphometry studies. J Affect Disord. 2012;138(1-2):9-18.
68. Smith R, Chen K, Baxter L, Fort C, Lane RD. Antidepressant effects of sertraline associated with volume increases in dorsolateral prefrontal cortex. J Affect Disord. 2013;146(3):414-9.
69. Liao Y, Huang X, Wu Q, et al. Is depression a disconnection syndrome? Meta-analysis of diffusion tensor imaging studies in patients with MDD. J Psychiatry Neurosci. 2013;38(1):49-56.
70. Kozel FA, Johnson KA, Nahas Z, et al. Fractional anisotropy changes after several weeks of daily left high-frequency repetitive transcranial magnetic stimulation of the prefrontal cortex to treat major depression. J ECT. 2011;27(1):5-10.
71. Peng H, Zheng H, Li L, et al. High-frequency rTMS treatment increases white matter FA in the left middle frontal gyrus in young patients with treatment-resistant depression. J Affect Disord. 2012;136(3):249-57.
72. Wang L, Hermens DF, Hickie IB, Lagopoulos J. A systematic review of resting-state functional-MRI studies in major depression. J Affect Disord. 2012;142(1-3):6-12.
73. Posner J, Hellerstein DJ, Gat I, et al. Antidepressants normalize the default mode network in patients with dysthymia. JAMA Psychiatry. 2013;70(4):373-82.
74. Brunoni AR, Lopes M, Fregni F. A systematic review and metaanalysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression. Int J Neuropsychopharmacol. 2008;11(8):1169-80.
75. Molendijk ML, Spinhoven P, Polak M, et al. Serum BDNF concentrations as peripheral manifestations of depression: evidence from a systematic review and meta-analyses on 179 associations (N=9484). Mol Psychiatry. 2014;19(7):791-800.
76. Brunoni AR, Baeken C, Machado-Vieira R, Gattaz WF, Vanderhasselt MA. BDNF blood levels after electroconvulsive therapy in patients with mood disorders: a systematic review and meta-analysis. World J Biol Psychiatry. 2014;15(5):411-8.
77. Brunoni AR, Machado-Vieira R, Zarate CA Jr., et al. BDNF plasma levels after antidepressant treatment with sertraline and transcranial direct current stimulation: results from a factorial, randomized, shamcontrolled trial. Eur Neuropsychopharmacol. 2014;24(7):1144-51.
78. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med. 2008;358(3):252-60.
79. Rothmann MD, Wiens BL, Chan ISF. Design and analysis of noninferiority trials. Boca Raton: Taylor & Francis Group; 2012.
80. Huitfeldt B, Hummel J, European Federation of Statisticians in the Pharmaceutical Industry (EFSPI). The draft FDA guideline on non-inferiority clinical trials: a critical review from European pharmaceutical industry statisticians. Pharm Stat. 2011;10(5):414-9.
81. Nutt D, Allgulander C, Lecrubier Y, Peters T, Wittchen U. Establishing non-inferiority in treatment trials in psychiatry: guidelines from an Expert Consensus Meeting. J Psychopharmacol. 2008;22(4):409-16.
82. Middleton H, Shaw I, Hull S, Feder G. NICE guidelines for the management of depression. BMJ. 2005;330(7486):267-8.
83. Guidance for Industry Non-Inferiority Clinical Trials; 2010. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM202140.pdf. Accessed in 2015 (Jan 7).
84. European Medicines Agency. Pre-authorisation Evaluation of Medicines for Human Use. Guideline on the choice of the noninferiority margin; 2004. Available from: http://www.emea.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003636.pdf. Accessed in 2015 (Jan 7).
85. Mulla SM, Scott IA, Jackevicius CA, You JJ, Guyatt GH. How to use a noninferiority trial: users’ guides to the medical literature. JAMA. 2012;308(24):2605-11.
86. Vigod S, Dennis CL, Daskalakis Z, et al. Transcranial direct current stimulation (tDCS) for treatment of major depression during pregnancy: study protocol for a pilot randomized controlled trial. Trials. 2014;15:366.
87. Knotkova H, Rosedale M, Strauss SM, et al. Using Transcranial Direct Current Stimulation to Treat Depression in HIV-Infected Persons: The Outcomes of a Feasibility Study. Front Psychiatry. 2012;3:59.
88. Valiengo LC, Bensenor IM, Lotufo PA, Fraguas R Jr, Brunoni AR. Transcranial direct current stimulation and repetitive transcranial magnetic stimulation in consultation-liaison psychiatry. Braz J Med Biol Res. 2013;46(10):815-23.
89. Palm U, Keeser D, Schiller C, et al. Skin lesions after treatment with transcranial direct current stimulation (tDCS). Brain Stimul. 2008;1(4):386-7.
90. Palm U, Fintescu Z, Obermeier M, et al. Serum levels of brain-derived neurotrophic factor are unchanged after transcranial direct current stimulation in treatment-resistant depression. J Affect Disord. 2013;150(2):659-63.
91. Brunoni AR, Machado-Vieira R, Zarate CA Jr., et al. Assessment of non-BDNF neurotrophins and GDNF levels after depression treatment with sertraline and transcranial direct current stimulation in a factorial, randomized, sham-controlled trial (SELECT-TDCS): An exploratory analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2015;56:91-6.
92. Player M, Taylor J, Weickert CS, et al. Increase in PAS-induced neuroplasticity after a treatment course of transcranial direct current stimulation for depression. J Affect Disord. 2014;167:140-7.
93. Powell TY, Boonstra TW, Martin DM, Loo CK, Breakspear M. Modulation of cortical activity by transcranial direct current stimulation in patients with affective disorder. PLoS One. 2014;9(6):e98503.
94. Wolkenstein L, Plewnia C. Amelioration of cognitive control in depression by transcranial direct current stimulation. Biol Psychiatry. 2013;73(7):646-51.
95. Oliveira JF, Zanao TA, Valiengo L, et al. Acute working memory improvement after tDCS in antidepressant-free patients with major depressive disorder. Neurosci Lett. 2013;537:60-4.
96. Zanao TA, Moffa AH, Shiozawa P, et al. Impact of Two or Less Missing Treatment Sessions on tDCS Clinical Efficacy: Results From a Factorial, Randomized, Controlled Trial in Major Depression. Neuromodulation. 2014;17(8):737-742.